- List compiled by David Shulkin, M.D., 9th Secretary of the US Department of Veteran Affairs
- Saama honored in Drug Development and Clinical Trials category
- Saama’s AI solutions counterbalance COVID-19 disruption of clinical trials
CAMPBELL, CA – (November 30, 2020) – Saama Technologies, Inc. (“Saama”), the #1 AI clinical analytics platform company, announced today that it has been named to the “2020 Inaugural List of Most Innovative Companies in Healthcare.” The list was created by David Shulkin, M.D., President of Shulkin Solutions LLC and the Ninth Secretary of the US Department of Veterans Affairs, to identify and acknowledge companies that are leading the way in innovation within the medical industry.
Saama was selected by Dr. Shulkin as the leading innovator in the Drug Development and Clinical Trials category because it has “…incredible analytics tools for drug development that use artificial intelligence to shorten the time required to bring a new drug to market and improve performance on studies and across study sites.”
“With a worldwide pandemic underway, we are seeing more innovation in our healthcare system than any other period in history. There never has been a more important time for our industry, and this recognition is just one way of acknowledging Saama for rising to the challenge,” said Dr. Shulkin.
“Saama is committed, now more than ever before, to equipping our biopharma partners with advanced AI-enabled software that empowers them to slingshot safe and effective new therapies to market for the patients who need them,” said Suresh Katta, Founder and CEO of Saama Technologies. “We are extremely proud to be recognized by Dr. Shulkin as one of the most innovative companies in life sciences alongside other outstanding organizations, such as Pfizer, Moderna, Lilly, and Regeneron, that are truly helping improve human health during a year that has been filled with challenges.”
About Saama Technologies, Inc.
Saama is the #1 AI clinical analytics platform company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs. Today, over 50 biotech companies use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform on more than 1,500 studies, including many of the top 20 pharmaceutical companies. LSAC’s rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster.